Nanocarriers in Cardiovascular Medicine: Current Applications and Future Perspectives
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".
Deadline for manuscript submissions: 31 August 2025 | Viewed by 100
Special Issue Editors
Interests: antihypertensive; antiatherogenic; cardioprotective; diuretic; lipid-lowering; vasodilator
Special Issues, Collections and Topics in MDPI journals
Interests: animal model; pharmacokinetics; drug information; pharmacodynamics; drug metabolism; pharmaceutical development; medical pharmacology; pharmacy education; drug toxicity; therapeutics; biopharmaceutics; pharmaceutical education; experimental pharmacology; pre-clinical development; preclinical toxicology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Cardiovascular diseases (CVD) are the main causes of illness and death globally. Hypertension is the leading risk factor exacerbating the occurrence, severity, and advancement of different types of cardiovascular diseases, which include arteriosclerosis and thrombosis. The associations among hypertension, arteriosclerosis, and other cardiovascular disorders increases the risk of undesirable outcomes in different patient groups. There are various options available for treating CVDs, including synthetic drugs and herbal medicines. However, numerous compounds and extracts have not yet undergone thorough scientific investigation regarding the use of nanocarriers. Nanocarriers can improve medication maintenance in the circulatory system, increase drug–target interaction, and reduce undesirable effects. Although nanocarriers offer therapeutic advantages, systematic efforts are still needed in order to establish the effectiveness and safety of these formulations.
For this Special Issue, we invite researchers to submit studies on nanocarrier design, targeted drug delivery, pharmacokinetics, and pharmacodynamics, focusing on advancements in the treatment of cardiovascular diseases. We will accept both original research and review articles. Potential submission topics include, but are not restricted to, the following:
- Nanoparticle-delivered dosage forms;
- Characterization of nanocarrier formulations;
- Quality control in nanocarrier development;
- Excipient–drug interactions;
- Pharmacokinetic studies in nanocarrier discovery;
- Pre-clinical and clinical studies on nanocarrier formulations;
- Review studies on the use of nanocarriers in cardiovascular diseases.
Dr. Arquimedes Gasparotto Junior
Dr. Francislaine Aparecida Dos Reis Lívero
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- drug delivery
- biopharmaceutical
- quality control
- nanocarriers
- nanoparticle
- cardioprotection
- hypertension
- drug development
- arteriosclerosis
- thrombosis
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
